Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130163 | 0.85 | DGAT1 (0.40) | TSHRDGAT1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL25755855 | 0.85 | NOTUM (0.49) | DGAT1NPC1MEN1KMT2A | |
| SCHEMBL128691 | 0.84 | DGAT1 (0.39) | TSHRDGAT1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL2960376 | 0.80 | CA12 (0.40) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL23780721 | 0.77 | DGAT1 (0.37) | DGAT1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL30807913 | 0.77 | KMT2A (0.45) | TSHRDGAT1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL29442160 | 0.77 | DGAT1 (0.37) | DGAT1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL566860 | 0.77 | KMT2A (0.45) | TSHRDGAT1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL24630843 | 0.77 | PDE4B (0.42) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL14255842 | 0.76 | ALDH1A1 (0.44) | DGAT1ALDH1A1KDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4313300-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117460723-A | Pharmaceutical compounds | 杜克街生物有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022207752-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | TSHR 3231/4885DGAT1 3365/4885ALDH1A1 2181/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TSHR 1437/4885DGAT1 3938/4885ALDH1A1 4805/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TSHR 1437/4885DGAT1 3938/4885ALDH1A1 4805/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | TSHR 1437/4885DGAT1 3938/4885ALDH1A1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.